middle.news
Arovella Advances CAR-iNKT Trials with $14.4 Million Cash Backing
12:15pm on Monday 27th of July, 2026 AEST
•
Biotechnology
Read Story
Arovella Advances CAR-iNKT Trials with $14.4 Million Cash Backing
12:15pm on Monday 27th of July, 2026 AEST
Key Points
Ethics approval received for ALA-101 phase 1 trial
First clinical batch of ALA-101 manufactured and under testing
Solid tumour program ALA-105 shows durable preclinical activity
Board reshuffle and new acting CEO appointed
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE